– CANADA, Vancouver – Redfund Capital Corp (CSE:LOAN / (FRA:O3X4 /OTC:PNNRF), today announced the appointment of Amanda de Freitas to the Board of Directors.
Amanda de Freitas is a Toronto based regulatory compliance executive and lobbyist and specializes in Canadian cannabis legislation. She is the CEO of Cannaceutical Canada Ltd, a management consulting firm that focuses on global medical cannabis supply transactions and deal development. Amanda is also President and founder of CannaBizSolutions Company, a firm that’s primary focus is on domestic medical and adult use cannabis businesses, helping assist them with their regulatory compliance, licensing, corporate and product development strategies. She is a frequent panelist and speaker at Canadian Medical Cannabis conferences.
“Amanda has become a trailblazer in the Canadian cannabis sector. She has ushered many startups in the Cannabis space from simple visions to legalization and strong revenues. She continues to be the female voice to many women in Canada who are quietly becoming global players in the cannabis sector. On behalf of our entire board, it is our pleasure to welcome another ‘Woman of Weed’ to the capital markets and Redfund.”
The Company further notes that Mr. Jack Bal has resigned from his position on the Board of Directors effective August 5, 2018 and the Company thanks him for his service.
About Redfund Capital
Redfund intends to provide debt and equity funding in the mid-to-late stages of a target company’s development, or in technologies that are developed and validated by revenues. The present focus of the merchant bank is on medical cannabis, hemp and CBD-related, healthcare-related target companies.
For more information : http://www.redfundcapital.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
Comments are closed.